Symbols / ASCO
ASCO Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- Bladder-preserving cancer care: new Signatera MRD data from ASCO GU - Stock Titan Fri, 27 Feb 2026 08
- ASCO 2025 movers – bispecifics to the rescue | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline hu, 05 Jun 2025 07
- ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset - Fierce Biotech Sun, 01 Jun 2025 07
- ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech ue, 03 Jun 2025 07
- Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU - TechStock² Fri, 13 Feb 2026 08
- Bladder and prostate cancer care get genomic focus in Veracyte’s ASCO GU data - Stock Titan ue, 24 Feb 2026 08
- H.C. Wainwright maintains Krystal Biotech stock Buy rating at ASCO 2025 - Investing.com Nigeria ue, 03 Jun 2025 07
- Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha Wed, 02 Jul 2025 07
- ASCO 2025 preview – Kura looks similar to Syndax | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline ue, 27 May 2025 07
- First Studies Reported Ahead of 2025 ASCO Annual Meeting - Oncology News Central hu, 22 May 2025 07
- ASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study - Fierce Biotech Mon, 02 Jun 2025 07
- Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha hu, 29 May 2025 07
- Bladder cancer trial shares new results from 25 patients at ASCO - Stock Titan hu, 22 Jan 2026 08
- Myriad cancer tests at ASCO-GU challenge prostate risk rules - Stock Titan ue, 24 Feb 2026 08
- Breakthrough: Natera's Cancer Detection Test Shows Near-Perfect Accuracy Across 5 Cancer Types at ASCO 2025 - Stock Titan Mon, 02 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ASCO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|